David Mack

Senior Scientist, CHEO Research Institute

Dr. Mack is currently a Professor of Pediatrics at the University of Ottawa and Senior Scientist at the CHEO Research Institute. His Pediatric Gastroenterology Fellowship training was completed at the Hospital for Sick Children, University of Toronto. Following training, Dr. Mack was appointed to Faculty of Medicine at the University of Nebraska Medical Centre.

In 2001, he returned to Ottawa with a mandate and a vision to develop a Division of Pediatric Gastroenterology, Hepatology and Nutrition. Aligning excellence, staying focused on the goals, consistency, optimism, patience, integrity, respectfulness, passion and communication defined his tenure in leading the Division and developing IBD research endeavours. Dr. Mack is currently the Director of the CHEO IBD Centre, studying the importance and role of the intestinal microbiome in IBD.

He recently received the Canadian Association of Gastroenterology Distinguished Service Award and University of Ottawa Faculty of Medicine Distinguished Clinical Research Chair

Research Projects

  1. Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children


    Conclusions: A combination of the white blood cell count, erythrocyte sedimentation rate, and either PLT or albumin is the best predictive subset of standard laboratory tests to identify severe from nonsevere clinical or mucosal disease at diagnosis in relation to objective clinical scores.

  2. Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn’s disease


    In this study, the proteolytic peptides generated from each microbiome sample were aliquoted for both metaproteomics and lysine acetylomics analysis. Kac peptides from the first aliquot were enriched using a seven-plex anti-Kac peptide antibody cocktail; the second aliquot was directly analyzed for metaproteome profiling

  3. Increased Intestinal Permeability is Associated with Later Development of Crohn’s Disease


    Increased intestinal permeability is associated with later development of CD; these findings support a model in which altered intestinal barrier function contributes to pathogenesis. Abnormal gut barrier function might serve as a biomarker for risk of CD onset.

  4. Phenotypic Variation in Paediatric Inflammatory Bowel Disease by Age: A Multicentre Prospective Inception Cohort Study of the Canadian Children IBD Network


    Paris classification of age at diagnosis is supported by age-related increases in ileal disease until age 10 years. Other phenotypic features, including severity, are similar across all ages. Linear growth is less impaired in CD than in historical cohorts, reflecting earlier diagnosis.

  5. Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease: Results from the ImageKids Study


    This study has confirmed that FC is useful, and overall best, marker to monitor mucosal inflammation in inflammatory bowel disease. FA12, however, appears to be a more suitable maker for prediction of mucosal healing in children.